First ever vaccine listed under WHO emergency use.

▴ First ever vaccine listed under WHO emergency use.
WHO today listed the nOPV2 vaccine (Bio Farma, Indonesia) for emergency use to address the rising cases of a vaccine-derived polio strain in a number of African and East Mediterranean countries.

WHO today listed the nOPV2 vaccine (Bio Farma, Indonesia) for emergency use to address the rising cases of a vaccine-derived polio strain in a number of African and East Mediterranean countries. Countries in WHO’s Western Pacific and South-East Asia regions are also affected by these outbreaks. The emergency use listing, or EUL, is the first of its kind for a vaccine and paves the way for a potential listing of COVID-19 vaccines.

The world has made incredible progress toward polio eradication, reducing polio cases by 99.9% in the last 30 years. But the last steps to ending this disease are proving the most difficult, particularly with continuing outbreaks of circulating vaccine-derived polioviruses (cVDPVs).

cVDPVs are rare and occur if the weakened strain of the poliovirus contained in the oral polio vaccine (OPV) circulates among under-immunized populations for a long time. If not enough children are immunized against polio, the weakened virus can pass between individuals and over time genetically revert to a form that can cause paralysis. Type 2 cVDPVs are currently the most prevalent form of the vaccine-derived virus.

The EUL procedure and how it could help to speed up access to a future COVID-19 vaccine

The EUL procedure assesses the suitability of yet to be licensed health products during public health emergencies, such as polio and COVID. The objective is to make these medicines, vaccines, and diagnostics available faster to address the emergency. The assessment essentially weighs the threat posed by the emergency against the benefit that would accrue from the use of the product based on a robust body of evidence.

The procedure was introduced during the West Africa Ebola outbreak of 2014-2016 when multiple Ebola diagnostics received emergency use listing; since then, numerous COVID-19 diagnostics have also been listed. The nOPV2 is the first such listing for a vaccine.

The EUL pathway involves a rigorous assessment of phase II and phase III clinical trial data as well as substantial additional data on safety, efficacy, and manufacturing quality. These data are reviewed by independent experts who consider the current body of evidence on the vaccine under consideration, the plans for monitoring its use, and the plans for further studies.

Experts from individual national authorities are invited to participate in the EUL review and are engaged to help facilitate the necessary country-level decision process for authorization of use. Once a vaccine has been listed for WHO emergency use, WHO engages its regional regulatory networks and partners to sensitize national health authorities on the vaccine and its anticipated benefits based on data from clinical studies to date.

In addition to deciding whether to use the vaccine, each country needs to complete a readiness process for the implementation of the vaccine under the EUL. The company producing the vaccine also commits to continue to generate data to enable full licensure and WHO prequalification of the vaccine. WHO prequalification will assess additional clinical data generated from vaccine trials and deployment on a rolling basis to ensure the vaccine continues to meet the necessary standards of quality, safety, and efficacy for broader availability

Tags : #WHO #nOPV2 #vaccine #Polio #EUL #COVID-19vaccine

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Is Your Cooking Oil Poisoning You? The Truth About Seed OilsMarch 11, 2025
Think Before You Bite: How Fatty Foods Can Trigger Brain Damage in Just 3 DaysMarch 11, 2025
Ditch the Pills: The Secret to Beating Insomnia is in Your WorkoutMarch 11, 2025
The University of Tasmania invites applications for Master of Public HealthMarch 11, 2025
CBM India Celebrates International Women's Day with Free Eye Screening in HyderabadMarch 11, 2025
Is patriarchy petrifying governments to deliver on gender equality?March 11, 2025
Change happens when gender inequality survivors join hands to stop TB March 10, 2025
Arogya World Hosts #RunInRed With 1500+ Bengalureans To Raise Awareness on Women’s Heart HealthMarch 10, 2025
Sharda Group Launches Sharda Care - Healthcity, a State-of-the-Art Facility with Smart Infrastructure in Greater NoidaMarch 10, 2025
Can Just Three Days of Junk Food Harm Your Brain? Science Says YesMarch 08, 2025
Your Night Shifts Might Be Damaging Your DNA: Here’s How to Fight BackMarch 08, 2025
India’s Women: Empowered on Paper, Struggling in RealityMarch 08, 2025
NephroPlus to Launch Nationwide Free Health Screening Campaign to Commemorate World Kidney Day 2025 March 07, 2025
Skinny But Sick? Is our Body Mass Index Misleading UsMarch 07, 2025
Scientists Stumble Upon a Cancer-Fighting Secret Hidden in Your Medicine CabinetMarch 07, 2025
The Bitter Truth About Butter: Is our Favourite Spread Cutting our Life Short?March 07, 2025
March 07, 2025
March 06, 2025
University of Leeds scientists offer hope for people facing chronic painMarch 06, 2025
Impact of excessive use of gym supplements on gym enthusiastsMarch 06, 2025